Business Context and Reporting Period
Redhill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company based in Tel Aviv, Israel, filed this Form 6-K on April 14, 2026. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's listing compliance status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
The primary material event is the receipt of a Nasdaq non-compliance notice dated April 8, 2026. The notice indicates that for the 30 consecutive business days ending April 2, 2026, the bid price of the Company's American Depositary Shares (ADSs) closed below the minimum $1.00 per share requirement under Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar day period, until October 5, 2026, to regain compliance.
- Compliance Criteria: To satisfy the requirement, the ADS bid price must close at $1.00 or more for a minimum of ten consecutive business days before the October 5, 2026 deadline.
- Operational Impact: Management states that operations are not affected by this notice, and ADSs will continue to trade on The Nasdaq Capital Market during the compliance period.
- Risk: Failure to regain compliance by the deadline could result in delisting from The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current trading price of RDHL ADSs to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for ten consecutive days of closing at or above $1.00 to confirm compliance.
- Review upcoming filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the listing deficiency.
- Check for any subsequent correspondence from Nasdaq regarding the extension or termination of the compliance period.